Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: (a) S. aureus post hoc population fits and observed data. Model fits (lines) based on population parameters are overlaid with the geometric means of the observed time-kill data (points) and observed geometric standard deviations (error bars) for each time-kill. Each column represents a culture condition (monoculture, coculture with the ATCC isolate, or coculture with the CRAB isolate), whereas each row represents the specific strain being observed. (b) A. baumannii post hoc population fits and observed data.

Article Snippet: The maximal activities of meropenem against the ATCC A. baumannii isolate were also similar during monoculture ( E Δ , −2.88 [95% CI, −2.43 to −3.33]) and coculture with ATCC S. aureus ( E Δ , −3.33 [95% CI, −2.94 to −3.73]) or CDC S. aureus ( E Δ , −2.95 [95% CI, −2.30 to −3.59]).

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: Empirical PK/PD model fits of log ratio areas. Log ratio areas from each time-kill study were modeled as a function of the meropenem concentration. Black lines indicate monoculture conditions, whereas red or black represents an S. aureus isolate cocultured with CRAB or ATCC A. baumannii, respectively. Yellow and green lines represent A. baumannii cocultured with CDC S. aureus and ATCC S. aureus, respectively. Each panel represents the bacterial species being observed.

Article Snippet: The maximal activities of meropenem against the ATCC A. baumannii isolate were also similar during monoculture ( E Δ , −2.88 [95% CI, −2.43 to −3.33]) and coculture with ATCC S. aureus ( E Δ , −3.33 [95% CI, −2.94 to −3.73]) or CDC S. aureus ( E Δ , −2.95 [95% CI, −2.30 to −3.59]).

Techniques: Concentration Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: Summary PK/PD statistics a

Article Snippet: The maximal activities of meropenem against the ATCC A. baumannii isolate were also similar during monoculture ( E Δ , −2.88 [95% CI, −2.43 to −3.33]) and coculture with ATCC S. aureus ( E Δ , −3.33 [95% CI, −2.94 to −3.73]) or CDC S. aureus ( E Δ , −2.95 [95% CI, −2.30 to −3.59]).

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: Mechanism-based pharmacodynamic model diagram. The S. aureus submodel is encircled in red, whereas the A. baumannii submodel is encircled in green. For each parameter affected by a covariate relationship, a subscripted prefix has been appended, with “s” signifying a covariate effect caused by the CDC S. aureus strain and “a” signifying a covariate effect caused by the CRAB strain. IC, inhibitory concentration.

Article Snippet: The maximal activities of meropenem against the ATCC A. baumannii isolate were also similar during monoculture ( E Δ , −2.88 [95% CI, −2.43 to −3.33]) and coculture with ATCC S. aureus ( E Δ , −3.33 [95% CI, −2.94 to −3.73]) or CDC S. aureus ( E Δ , −2.95 [95% CI, −2.30 to −3.59]).

Techniques: Concentration Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: Parameter estimates a

Article Snippet: The maximal activities of meropenem against the ATCC A. baumannii isolate were also similar during monoculture ( E Δ , −2.88 [95% CI, −2.43 to −3.33]) and coculture with ATCC S. aureus ( E Δ , −3.33 [95% CI, −2.94 to −3.73]) or CDC S. aureus ( E Δ , −2.95 [95% CI, −2.30 to −3.59]).

Techniques: Mutagenesis, Inhibition

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: A 2,500-subject Monte Carlo simulation. Meropenem in a 2-g 3hPI q8h was simulated over 48 h in 2,500 subjects for each mono- and coculture scenario explored in the time-kill studies. The resulting medians (solid lines) and 90th/10th prediction intervals (shaded regions) were plotted for each A. baumannii and S. aureus isolate.

Article Snippet: The maximal activities of meropenem against the ATCC A. baumannii isolate were also similar during monoculture ( E Δ , −2.88 [95% CI, −2.43 to −3.33]) and coculture with ATCC S. aureus ( E Δ , −3.33 [95% CI, −2.94 to −3.73]) or CDC S. aureus ( E Δ , −2.95 [95% CI, −2.30 to −3.59]).

Techniques:

Journal: Frontiers in Microbiology

Article Title: Embelin Restores Carbapenem Efficacy against NDM-1-Positive Pathogens

doi: 10.3389/fmicb.2018.00071

Figure Lengend Snippet: Embelin potentiates the activity of meropenem or biapenem against carbapenem-resistant pathogens (A–C) . Microdilution checkerboard analysis showing the combined effect of embelin and meropenem (A) , biapenem (B) and imipenem (C) selectively against K. pneumoniae ATCC BAA-2146 (MIC meropenem = 64 μg/ml, MIC biapenem = 8 μg/ml, MIC imipenem = 32 μg/ml)showing the average of three technical replicates. (D) FIC indices of embelin and meropenem against NDM-1 producing clinical isolates. (E) NDM-expressing Gram-negative pathogens were highly susceptible to the combination of meropenem (2 μg/ml) and embelin (from 2 to 16 μg/ml).

Article Snippet: When treated with 32 μg/ml embelin, the MICs of ATCC BAA-2146 against meropenem fell by up to 512-fold, 128-fold for biapenem and about 256-fold for imipenem.

Techniques: Activity Assay, Expressing

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

doi: 10.1128/aac.00440-23

Figure Lengend Snippet: MICs of meropenem and cefepime alone and in combination with BLIs against the panel of engineered P. aeruginosa strains producing various cloned β-lactamases

Article Snippet: Xeruborbactam at 4 or 8 μg/mL significantly increased meropenem potency against meropenem-resistant KPC-producing strains of Klebsiella pneumoniae (ATCC BAA-1705 and BAA ATCC-2814), NDM-1-producing strain of Escherichia coli (CDC 0069), and VIM-1-producing strain of K. pneumoniae (CDC 0135).

Techniques: Clone Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

doi: 10.1128/aac.00440-23

Figure Lengend Snippet: In vitro activity of meropenem plus xeruborbactam at 4 and 8 µg/mL and comparator BLI combination agents and comparator BLI combination agents against carbapenem-resistant strains of Enterobacterales with either partially functional or non-functional OmpK36 according to carbapenemase production ^a

Article Snippet: Xeruborbactam at 4 or 8 μg/mL significantly increased meropenem potency against meropenem-resistant KPC-producing strains of Klebsiella pneumoniae (ATCC BAA-1705 and BAA ATCC-2814), NDM-1-producing strain of Escherichia coli (CDC 0069), and VIM-1-producing strain of K. pneumoniae (CDC 0135).

Techniques: In Vitro, Activity Assay, Functional Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

doi: 10.1128/aac.00440-23

Figure Lengend Snippet: In vitro activity of meropenem alone and combined with xeruborbactam at 4 and 8 µg/mL and comparator BLI combination agents against carbapenem-resistant strains of Enterobacterales with cefepime-taniborbactam MIC >8 µg/mL

Article Snippet: Xeruborbactam at 4 or 8 μg/mL significantly increased meropenem potency against meropenem-resistant KPC-producing strains of Klebsiella pneumoniae (ATCC BAA-1705 and BAA ATCC-2814), NDM-1-producing strain of Escherichia coli (CDC 0069), and VIM-1-producing strain of K. pneumoniae (CDC 0135).

Techniques: In Vitro, Activity Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

doi: 10.1128/aac.00440-23

Figure Lengend Snippet: In vitro potency of meropenem in combination with xeruborbactam against CRE with cefepime-taniborbactam MIC values of >8 µg/mL. MEM-XER at 8 µg/mL, FEP-TAN at 4 µg/mL. FEP-TAN, cefepime-taniborbactam; MEM-XER, meropenem-xeruborbactam.

Article Snippet: Xeruborbactam at 4 or 8 μg/mL significantly increased meropenem potency against meropenem-resistant KPC-producing strains of Klebsiella pneumoniae (ATCC BAA-1705 and BAA ATCC-2814), NDM-1-producing strain of Escherichia coli (CDC 0069), and VIM-1-producing strain of K. pneumoniae (CDC 0135).

Techniques: In Vitro

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

doi: 10.1128/aac.00440-23

Figure Lengend Snippet: In vitro activity of meropenem and cefepime combined with xeruborbactam or taniborbactam against carbapenem-resistant strains of Enterobacterales with a functional or defective OmpK36 according to carbapenemase production ^a

Article Snippet: Xeruborbactam at 4 or 8 μg/mL significantly increased meropenem potency against meropenem-resistant KPC-producing strains of Klebsiella pneumoniae (ATCC BAA-1705 and BAA ATCC-2814), NDM-1-producing strain of Escherichia coli (CDC 0069), and VIM-1-producing strain of K. pneumoniae (CDC 0135).

Techniques: In Vitro, Activity Assay, Functional Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

doi: 10.1128/aac.00440-23

Figure Lengend Snippet: In vitro activity of meropenem or cefepime combined with xeruborbactam or taniborbactam against isogenic efflux and porin mutants of K. pneumoniae and their NDM-1-producing derivatives

Article Snippet: Xeruborbactam at 4 or 8 μg/mL significantly increased meropenem potency against meropenem-resistant KPC-producing strains of Klebsiella pneumoniae (ATCC BAA-1705 and BAA ATCC-2814), NDM-1-producing strain of Escherichia coli (CDC 0069), and VIM-1-producing strain of K. pneumoniae (CDC 0135).

Techniques: In Vitro, Activity Assay